Subcutaneous Daratumumab for Light Chain Amyloidosis: Efstathios Kastritis, MD

Recently, the FDA approved subcutaneous daratumumab in combination with bortezomib/cyclophosphamide/dexamethasone (VCd) for the treatment of patients with newly diagnosed amyloid light chain (AL) amyloidosis. In this interview, Efstathios Kastritis, MD, Associate Professor of Clinical Therapeutics at the National and Kapodistrian University of Athens and senior author of ANDROMEDA (NCT03201965), the study on which the approval was based, discusses the challenges of treating patients with AL...
Continue reading

Daratumumab/Carfilzomib/Dexamethasone for Multiple Myeloma: Meletios A. Dimopoulos, MD

Recently, the FDA approved a new treatment for multiple myeloma previously treated with one to three lines of therapy: daratumumab (Darzalex®, Janssen) in combination with carfilzomib and dexamethasone. In this interview, Meletios Dimopoulos, MD, principal investigator of the phase 3 CANDOR trial, which served as the basis for the approval, speaks with i3 Health regarding the benefits and adverse events of this new therapeutic combination, as well as additional advances in the treatment of relap...
Continue reading

New Daratumumab Combination Approved for Multiple Myeloma

The FDA has approved a new therapeutic combination involving daratumumab (Darzalex®, Janssen), carfilzomib, and dexamethasone for the treatment of adults with multiple myeloma previously treated with one to three lines of therapy. Daratumumab, the first CD37 monoclonal antibody to reach the market, has previously been approved for multiple myeloma in combination with bortezomib/thalidomide/dexamethasone for transplant-eligible newly diagnosed patients, in combination with lenalidomide/dexamethas...
Continue reading

Multiple Myeloma: Adding Daratumumab to Carfilzomib/Dexamethasone Enhances Efficacy

Results from the phase 3 CANDOR trial show that for relapsed/refractory multiple myeloma, adding daratumumab (D) to carfilzomib/dexamethasone (Kd) increases efficacy compared with Kd alone. "Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma," write the study investigators in their publication in The Lancet, led by Meletios Dimopoulos, MD, Professor and Chairman of Clinical Therapeutics at the Na...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.

Cron Job Starts